GOG 0252.

Trial name or title	GOG 0252
Methods	Study duration: projected to complete in 2016 Type of trial: US multicentre RCT Planned follow‐up duration: 5 years Patients are stratified according to disease stage and size of residual disease after initial staging/debulking surgery
Participants	Patients with FIGO stage II ‐ IV (no gross residual disease vs gross residual disease with lesion ≤ 1 cm vs any gross residual disease with lesion > 1 cm). Number to be randomised: 1500
Interventions	Patients are randomized to 1 of 3 treatment arms. See Table 4.
Outcomes	PFS, OS, adverse events and QOL
Starting date	Aug 2009
Contact information	Joan Walker USA 405‐271‐8707
Notes